Skip to main content
FDA committee backs Palforzia as peanut allergy treatment for kids
9/16/2019

Aimmune Therapeutics' Palforzia, formerly called AR101, an oral immunotherapy indicated as a treatment for pediatric patients with peanut allergies, gained the backing of the FDA's Allergenic Products Advisory Committee in a 7-2 vote. The vote was made on the condition that clinicians will guarantee that patients prescribed Palforzia are also given a valid epinephrine autoinjector prescription in case those undergoing treatment experience systemic allergic reactions as per the FDA's prerequisite of a Risk Evaluation and Mitigation Strategy.

Full Story: